Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Corline Biomedical AB is a Sweden-based biotechnology company that develops, manufactures, and markets heparin-based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are built on Corline Heparin Conjugate (CHC) technology, a specialized heparin conjugate serving as an anticoagulant pharmaceutical compound to prevent harmful blood clotting during surgery. Key offerings include Renaparin, designed for treating end-stage renal failure; Cytoparin, a cell therapy product aimed at patients with type 1 diabetes; and CHC, applied in the treatment of soft tissue injuries. Operating within the pharmaceuticals and biotech sector, Corline Biomedical AB focuses on innovative solutions that address critical needs in transplantation and advanced therapeutic areas. Founded in 1991 and headquartered in Uppsala, Sweden, the company plays a targeted role in advancing medical treatments through its proprietary heparin surface technology.
kr 1.60
+kr 0.02 (+1.27%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-192.81% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 21.7% YoY. Margins deteriorated 58.0pp alongside, both lines moving the wrong way.
Negative free cash flow of -kr 19M. The business is consuming cash, not generating it. Operating margin contracted 58.0pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 10M
▼ -21.7% YoY
Net Income (TTM)
-kr 14M
▲ +36.6% YoY
Op. Margin
-143.45%
▼ -58.0pp YoY
ROIC
-12.90%
▼ -1.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 19M
▼ -15.7% YoY
Op. Cash Flow (TTM)
-kr 17M
▲ +2.9% YoY
Net Debt
-kr 21M
Net Cash Position
Cash & Equiv.
kr 21M
3Y CAGR: -31.3%
Continue Research
Corline Biomedical AB (CLBIO.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Corline Biomedical AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Corline Biomedical AB scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -143.5% operating margin and a -12.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CLBIO.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.